T1	p 70 157	postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy
T2	p 331 439	postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT )
T3	p 450 550	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine
T4	p 2527 2580	postoperative stage II and III rectal cancer patients
T5	i 140 157	chemoradiotherapy
T6	i 381 399	capecitabine-based
T7	i 414 431	chemoradiotherapy
T8	i 434 437	CRT
T9	i 538 550	capecitabine
T10	i 567 578	oxaliplatin
T11	i 758 799	capecitabine and radiotherapy ( Cap-CRT )
T12	i 837 899	capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT )
T13	i 2145 2156	Cap-Oxa-CRT
T14	i 2338 2345	Cap-CRT
T15	i 2614 2631	chemoradiotherapy
T16	i 2635 2647	capecitabine
T17	i 2652 2663	oxaliplatin
T18	o 46 66	acute adverse events
T19	o 299 327	acute adverse events ( AEs )
T20	o 902 916	Adverse events
T21	o 946 1016	Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 )
T22	o 1213 1222	acute AEs
T23	o 1403 1406	AEs
T24	o 1600 1603	AEs
T25	o 1606 1614	Diarrhea
T26	o 1635 1637	AE
T27	o 1644 1659	severe diarrhea
T28	o 1877 1892	severe diarrhea
T29	o 1975 1990	severe diarrhea
T30	o 2229 2244	severe diarrhea
T31	o 2398 2413	severe diarrhea
T32	o 2514 2523	acute AEs